VolitionRX Limited (VNRX)
| Market Cap | 214.96M |
| Revenue (ttm) | 6,313 |
| Net Income (ttm) | -18.77M |
| Shares Out | 47.03M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $4.46 |
| Previous Close | $4.01 |
| Change ($) | 0.45 |
| Change (%) | 11.22% |
| Day's Open | 4.02 |
| Day's Range | 4.02 - 4.47 |
| Day's Volume | 403,218 |
| 52-Week Range | 2.47 - 4.99 |
Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of c...
VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death f...
DOUGLAS, Isle of Man--(BUSINESS WIRE)--Cotterford Co. Ltd. (“Cotterford”) the beneficial owner of approximately 26% of the outstanding shares of VolitionRX Limited (“Volition”) (AMEX: VNRX), t...
VolitionRx (VNRX) Investor Presentation - Slideshow
VolitionRx Limited's (VNRX) CEO Cameron Reynolds on Q3 2019 Results - Earnings Call Transcript
These healthcare stocks are all worth a "buy" now. The healthcare sector will keep chugging along despite market volatility.
VolitionRX Limited (VNRX) CEO Cameron Reynolds on Q2 2019 Results - Earnings Call Transcript
VolitionRX Ltd. (VNRX) CEO Cameron Reynolds on Q4 2018 Results - Earnings Call Transcript
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.
| Industry Diagnostics & Research | |
| Stock Exchange NYSEAMERICAN | Ticker Symbol VNRX |
Analyst Forecasts
According to 3 analysts, the average rating for VolitionRX stock is "Strong Buy." The 12-month stock price forecast is 7.16, which is an increase of 60.54% from the latest price.